SCHEMBL12486739

SCHEMBL12486739

CCCc1cc(N2CCCCC2CCO)nc(Nc2ccc(C)c(Cl)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 5/20 0.40
▸ CDK9 P50750 5/20 0.40
▸ CCNE1 P24864 3/20 0.40
▸ CDK7 P50613 3/20 0.40
▸ CCNT1 O60563 2/20 0.40
▸ CCNK O75909 2/20 0.40
▸ CCNH P51946 2/20 0.40
▸ MNAT1 P51948 2/20 0.40
▸ CDK13 Q14004 2/20 0.40
▸ CDK12 Q9NYV4 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ CDK5 Q00535 4/20 0.38
▸ CDK1 P06493 4/20 0.38
▸ NPY5R Q15761 1/20 0.37
▸ MAPT P10636 3/20 0.37
▸ MEN1 O00255 4/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ USP2 O75604 2/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ GSK3A P49840 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12486688 0.91 TDP1 (0.42) TDP1MAPTMEN1KMT2AUSP2
SCHEMBL12486552 0.90 CDK2 (0.39) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12484883 0.90 CDK1 (0.43) TDP1CDK1MAPTMEN1KMT2A
SCHEMBL12484886 0.90 CDK1 (0.43) TDP1CDK1MAPTMEN1KMT2A
SCHEMBL12485930 0.90 CDK2 (0.39) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12486549 0.89 CDK2 (0.39) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12486147 0.88 CDK1 (0.46) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12486097 0.87 ALDH1A1 (0.44) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12484255 0.86 CTNNB1 (0.41) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12486229 0.86 CDK2 (0.38) CDK2CDK9CCNE1CDK7CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2020-05-05 — — US claimed
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2018-03-15 — — US claimed
US-9850227-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2017-12-26 — — US claimed
EP-2678331-B1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2016-04-27 — — EP claimed
EP-2678331-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2014-01-01 — — EP claimed
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2013-12-12 — — US claimed
WO-2012115478-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-08-30 — — WO claimed
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2020-05-05 — — US disclosed
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2018-03-15 — — US disclosed
US-9850227-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2017-12-26 — — US disclosed
EP-2678331-B1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2016-04-27 — — EP disclosed
EP-2678331-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2014-01-01 — — EP disclosed
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2013-12-12 — — US disclosed
WO-2012115478-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF HRH2, GIPR, SSTR4 CDK2 1458/4885CDK9 557/4885CCNE1 2906/4885
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof HRH2, GIPR, SSTR4 CDK2 1458/4885CDK9 557/4885CCNE1 2906/4885
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF HRH2, GIPR, SSTR4 CDK2 1458/4885CDK9 557/4885CCNE1 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback